American Healthcare REIT Inc Dossier - Source-backed chat

American Healthcare REIT Inc

AHRNYSE

SectorReal Estate

IndustryREIT - Healthcare Facilities

Beta (adjusted)0.83

Intrinsic Value $34.41median of 1 methodbased on filings through 30 Jun 2026

Market Price $51.26Price as of 30 Sep 2026

OvervaluedIntrinsic value is 33% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $11.2B

Enterprise Value $11.9B

Shares Outstanding 198.2M diluted

Next Earnings Date5 Nov 2026

Last ex-dividend30 Jun 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

American Healthcare REIT entered the second half of 2026 with strong operating momentum: second-quarter total-portfolio same-store NOI increased 13.2%, SHOP and ISHC growth reached 20.5% and 16.1%, normalized FFO was $0.54 per diluted share, and management raised full-year normalized FFO guidance to $2.15-$2.19. Net leverage improved to 2.5x despite substantial acquisition activity. These positives are balanced by rapid equity issuance, integration and execution demands from a large investment program. The resulting stance is Hold rather than Buy.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets15 analysts · as of 18 Aug 2026

Low · most bearish analyst$55.00

Mean target$62.13

High · most bullish analyst$70.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$55.0020%

Organic growth falls below guidance, newly acquired properties take longer to integrate, or continued equity issuance dilutes per-share benefits before acquired assets contribute fully. A reversal of the recent leverage improvement would compound the downside.

Base CaseCentral scenario

$62.1355%

Matches the consensus mean

Full-year normalized FFO and total-portfolio same-store NOI finish within the raised guidance ranges, acquisition-funded growth offsets incremental share issuance, and leverage remains manageable. The base case is operationally constructive but valuation-neutral.

Bull CaseUpside scenario

$70.0025%

Operating execution remains near the upper ends of FY2026 guidance, SHOP and ISHC continue producing double-digit same-store NOI growth, recent acquisitions integrate successfully, and the disclosed investment pipeline closes without materially weakening leverage or per-share growth.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Second-quarter 2026 total-portfolio same-store NOI grew 13.2%, including 20.5% in SHOP and 16.1% in ISHC; management described this as the tenth consecutive quarter of double-digit same-store NOI growth.
Management raised FY2026 normalized FFO guidance to $2.15-$2.19 per diluted share and total-portfolio same-store NOI growth guidance to 11.0%-13.0%.
Net debt to annualized adjusted EBITDA improved from 3.0x at March 31, 2026 to 2.5x at June 30, 2026 while the company completed $1.4 billion of investments during the first half and subsequent period reported with Q2 results.

Key Investment Risks

The August 2026 forward equity offering covered 13.25 million shares and approximately $712.2 million of expected gross proceeds, adding potential dilution and increasing dependence on timely deployment into accretive investments.
Portfolio growth is concentrated in the operating senior-housing and integrated-care segments; second-quarter same-store NOI growth was only 1.7% in outpatient medical and 2.1% in triple-net leased properties.
The company disclosed an investment pipeline exceeding $800 million but expressly stated that timing and completion were not guaranteed and excluded those prospective transactions from guidance.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.